Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

A Randomized, Double-blind, Placebo- and Active-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 1 Year in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents (CAIN457F2309) and A Four Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis (CAIN457F2309E1)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01350804

Acronym

NURTURE 1

Enrollment

551

Registered

2011-05-10

Start date

2011-09-30

Completion date

2015-02-28

Last updated

2016-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Rheumatoid Arthritis, RA, ACR, inflammatory joints

Brief summary

The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α agents. Patients received either secukinumab, placebo or abatacept (active comparator). The core study was completed. However, the extension study was prematurely terminated after the primary endpoint analysis of the core study at week 24 had demonstrated numerically higher efficacy for the active comparator abatacept compared to secukinumab.

Interventions

BIOLOGICALAIN457

AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.

BIOLOGICALPlacebo

Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.

BIOLOGICALAbatacept

Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or non-pregnant, non-lactating female patients * Presence of RA classified by ACR 2010 revised criteria for at least 3 months before screening * At Baseline: Disease activity criteria defined by \>= 6 tender joints out of 68 and \>= 6 swollen joints out of 66 WITH at least 1 of the following at screening: * Anti-Cyclic Citrullinated Peptide (Anti-CCP) antibodies positive OR * Rheumatoid Factor positive AND WITH at least 1 of the following at screening: * High sensitivity C-Reactive Protein (hsCRP) \>= 10 mg/L OR * Erythrocyte Sedimentation Rate (ESR) \>= 28 millimeter (mm)/1st hour * Patients must have been taking at least one anti-TNF-α agent given at an approved dose for at least 3 months before randomization and have experienced an inadequate response to treatment or have been intolerant to at least one administration of an anti-TNF-α agent * Patients must be taking MTX or any other DMARD (but not more than 1 DMARD) for at least 3 months before randomization and have to be on a stable dose at least 4 weeks before randomization (7.5 to 25 mg/week for MTX or other DMARD at maximum tolerated dose)

Exclusion criteria

* Chest x-ray with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician * RA patients functional status class IV according to the ACR 1991 revised criteria * Patients who have ever received biologic immunomodulating agents except for those targeting TNFα * Previous treatment with any cell-depleting therapies Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20).	week 24	ACR20 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20% improvement in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire \[HAQ-DI\] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR20 response results at week 24 used non-responder imputation.

Secondary

Measure	Time frame	Description
Change From Baseline in Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)	baseline, week 24	The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, are you able to... perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.
Percentage of Participants Achieving ACR50	week 24	ACR50 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 50% improvement in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire \[HAQ-DI\] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR50 response results at week 24 used non-responder imputation.
Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24	ACR20, ACR 50 and ACR 70 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20%, 50% and/or 70% improvement, respectively, in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire \[HAQ-DI\] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR).
Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52	ACR20, ACR 50 and ACR 70 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20%, 50% and/or 70% improvement, respectively, in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire \[HAQ-DI\] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR20, ACR50 and ACR70 response results from baseline up to week 52 were based on observed data, i.e. without imputation.
Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24	The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, are you able to... perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.
Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP)	baseline, week 24	The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement.
Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24	The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement.
Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52	The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement. The DAS28-CRP results from baseline up to week 52 were based on observed data, i.e. without imputation.
Change From Baseline in hsCRP - Observed Data	baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52	Blood samples were obtained to identify the presence of inflammation, to determine its severity and to monitor response to treatment. A negative change from baseline indicates improvement. The hsCRP results from baseline up to week 52 were based on observed data, i.e. without imputation.
Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52	Blood samples were obtained to monitor disease activity and response to treatment. A negative change from baseline indicates improvement. The ESR results from baseline up to week 52 were based on observed data, i.e. without imputation.
Change From Baseline in HAQ-DI - Observed Data	baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52	The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, are you able to... perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement. The HAQ-DI results from baseline up to week 52 were based on observed data, i.e. without imputation.

Countries

Brazil, Bulgaria, Canada, Colombia, Czechia, France, Germany, Hungary, Italy, Mexico, Romania, Russia, Slovakia, Spain, United States

Participant flow

Recruitment details

At baseline, participants were randomized to 1 of 4 treatment groups. Placebo non-responders at week16 were re-randomized to receive AIN457 75mg or AIN457 150mg. Placebo responders at Week16 were re-randomized to receive AIN457 75mg or AIN457 150mg at Week24. Fifteen participants from the placebo group discontinued prior to re-randomization.

Pre-assignment details

Abatacept responders at Week16 continued on abatacept and non-responders at Week 16 were re-randomized to begin either AIN457 75mg or AIN457 150mg at Week 24. Of the 551 core study participants, 254 participants entered the extension study.

Participants by arm

Arm	Count
AIN457 10mg/kg - 75 mg Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.	138
AIN457 10mg/kg - 150 mg Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.	137
Placebo Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (\>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.	138
Abatacept Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).	138
Total	551

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Core Study	Adverse Event	8	10	8	8
Core Study	Death	1	1	1	0
Core Study	Lack of Efficacy	16	19	18	5
Core Study	Lost to Follow-up	3	0	2	1
Core Study	Physician Decision	1	0	1	3
Core Study	Protocol deviation	1	0	1	0
Core Study	Study terminated by Sponsor	0	0	0	2
Core Study	Withdrawal by Subject	11	17	16	7
Extension Study, Weeks 52 - 260	Adverse Event	3	1	2	3
Extension Study, Weeks 52 - 260	Lack of Efficacy	4	4	0	1
Extension Study, Weeks 52 - 260	Lost to Follow-up	0	1	0	0
Extension Study, Weeks 52 - 260	Physician Decision	1	0	2	0
Extension Study, Weeks 52 - 260	Study terminated by Sponsor	67	67	64	16
Extension Study, Weeks 52 - 260	Withdrawal by Subject	5	6	4	3

Baseline characteristics

Characteristic	AIN457 10mg/kg - 75 mg	AIN457 10mg/kg - 150 mg	Placebo	Abatacept	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	27 Participants	34 Participants	32 Participants	23 Participants	116 Participants
Age, Categorical Between 18 and 65 years	111 Participants	103 Participants	106 Participants	115 Participants	435 Participants
Sex: Female, Male Female	119 Participants	109 Participants	115 Participants	107 Participants	450 Participants
Sex: Female, Male Male	19 Participants	28 Participants	23 Participants	31 Participants	101 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —
other Total, other adverse events	144 / 218	146 / 215	51 / 139	78 / 137
serious Total, serious adverse events	30 / 218	28 / 215	7 / 139	9 / 137

Outcome results

Primary

Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20).

ACR20 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20% improvement in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire \[HAQ-DI\] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR20 response results at week 24 used non-responder imputation.

Time frame: week 24

Population: Full analysis set: the full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.

Arm	Measure	Value (NUMBER)
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20).	28.3 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20).	30.7 Percentage of participants
Placebo	Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20).	18.1 Percentage of participants
Abatacept	Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20).	42.8 Percentage of participants

p-value: 0.045895% CI: [1, 3.2]Regression, Logistic

p-value: 0.015295% CI: [1.1, 3.5]Regression, Logistic

Secondary

Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP)

The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement.

Time frame: baseline, week 24

Population: Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and week 24 were analyzed. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.

Arm	Measure	Value (LEAST_SQUARES_MEAN)	Dispersion
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP)	-1.47 score on a scale	Standard Error 0.115
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP)	-1.47 score on a scale	Standard Error 0.119
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP)	-1.02 score on a scale	Standard Error 0.163
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP)	-2.07 score on a scale	Standard Error 0.128

Secondary

Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data

Time frame: baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Population: Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and each post-baseline time point were analyzed for that post-baseline time point. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.

Arm	Measure	Group	Value (MEAN)	Dispersion
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-1.181 score on a scale	Standard Deviation 1.1821
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk44,n=96,88,na,na,28,27,20,18,84,15,16	-1.764 score on a scale	Standard Deviation 1.3227
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-1.163 score on a scale	Standard Deviation 1.1656
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk48,n=94,88,na,na,28,26,18,19,76,12,14	-1.761 score on a scale	Standard Deviation 1.3152
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-1.427 score on a scale	Standard Deviation 1.3266
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk32,n=103,97,na,na,33,39,23,22,87,17,16	-1.738 score on a scale	Standard Deviation 1.2783
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk16,n=126,116,114,128,36,36,21,21,94,15,19	-1.225 score on a scale	Standard Deviation 1.2866
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk1,n=131,129,130,129,39,35,21,22, 95,17,17	-0.886 score on a scale	Standard Deviation 0.9784
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-1.467 score on a scale	Standard Deviation 1.3116
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk52,n=92,86,na,na,28,26,20,18,79,15,15	-1.839 score on a scale	Standard Deviation 1.3755
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk36,n=101,92,na,na,30,30,21,20,84,18,15	-1.737 score on a scale	Standard Deviation 1.4592
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.909 score on a scale	Standard Deviation 1.0331
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk28,n=115,103,na,na,33,35,21,21,86,17,18	-1.484 score on a scale	Standard Deviation 1.3216
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-1.229 score on a scale	Standard Deviation 1.1782
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk40,n=96,90,na,na,28,28,21,19,84,15,17	-1.742 score on a scale	Standard Deviation 1.3259
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk28,n=115,103,na,na,33,35,21,21,86,17,18	-1.819 score on a scale	Standard Deviation 1.3434
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-1.579 score on a scale	Standard Deviation 1.3221
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk52,n=92,86,na,na,28,26,20,18,79,15,15	-2.109 score on a scale	Standard Deviation 1.4
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.900 score on a scale	Standard Deviation 1.0284
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk48,n=94,88,na,na,28,26,18,19,76,12,14	-2.200 score on a scale	Standard Deviation 1.3293
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-1.150 score on a scale	Standard Deviation 1.1942
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk44,n=96,88,na,na,28,27,20,18,84,15,16	-1.932 score on a scale	Standard Deviation 1.285
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-1.283 score on a scale	Standard Deviation 1.1678
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk40,n=96,90,na,na,28,28,21,19,84,15,17	-1.788 score on a scale	Standard Deviation 1.1333
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-1.402 score on a scale	Standard Deviation 1.2182
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk1,n=131,129,130,129,39,35,21,22, 95,17,17	-0.759 score on a scale	Standard Deviation 0.8654
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk36,n=101,92,na,na,30,30,21,20,84,18,15	-1.820 score on a scale	Standard Deviation 1.25
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk16,n=126,116,114,128,36,36,21,21,94,15,19	-1.455 score on a scale	Standard Deviation 1.3489
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk32,n=103,97,na,na,33,39,23,22,87,17,16	-1.966 score on a scale	Standard Deviation 1.177
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-1.569 score on a scale	Standard Deviation 1.2361
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk44,n=96,88,na,na,28,27,20,18,84,15,16	NA score on a scale	—
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-1.248 score on a scale	Standard Deviation 1.2915
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk1,n=131,129,130,129,39,35,21,22, 95,17,17	-0.211 score on a scale	Standard Deviation 0.6877
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk28,n=115,103,na,na,33,35,21,21,86,17,18	NA score on a scale	—
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-0.644 score on a scale	Standard Deviation 1.1356
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk40,n=96,90,na,na,28,28,21,19,84,15,17	NA score on a scale	—
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-1.164 score on a scale	Standard Deviation 1.2087
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.363 score on a scale	Standard Deviation 0.8388
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-0.742 score on a scale	Standard Deviation 1.233
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk36,n=101,92,na,na,30,30,21,20,84,18,15	NA score on a scale	—
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk52,n=92,86,na,na,28,26,20,18,79,15,15	NA score on a scale	—
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk16,n=126,116,114,128,36,36,21,21,94,15,19	-0.592 score on a scale	Standard Deviation 1.2557
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk32,n=103,97,na,na,33,39,23,22,87,17,16	NA score on a scale	—
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk48,n=94,88,na,na,28,26,18,19,76,12,14	NA score on a scale	—
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-0.492 score on a scale	Standard Deviation 0.8876
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-1.840 score on a scale	Standard Deviation 1.4144
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-1.989 score on a scale	Standard Deviation 1.4717
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-1.790 score on a scale	Standard Deviation 1.2356
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk36,n=101,92,na,na,30,30,21,20,84,18,15	NA score on a scale	—
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk44,n=96,88,na,na,28,27,20,18,84,15,16	NA score on a scale	—
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-1.095 score on a scale	Standard Deviation 1.0483
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk16,n=126,116,114,128,36,36,21,21,94,15,19	-1.691 score on a scale	Standard Deviation 1.2979
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk32,n=103,97,na,na,33,39,23,22,87,17,16	NA score on a scale	—
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk1,n=131,129,130,129,39,35,21,22, 95,17,17	-0.502 score on a scale	Standard Deviation 0.7539
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk28,n=115,103,na,na,33,35,21,21,86,17,18	NA score on a scale	—
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-1.541 score on a scale	Standard Deviation 1.1172
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk40,n=96,90,na,na,28,28,21,19,84,15,17	NA score on a scale	—
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk52,n=92,86,na,na,28,26,20,18,79,15,15	NA score on a scale	—
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.755 score on a scale	Standard Deviation 0.9234
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk48,n=94,88,na,na,28,26,18,19,76,12,14	NA score on a scale	—
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk52,n=92,86,na,na,28,26,20,18,79,15,15	-1.487 score on a scale	Standard Deviation 1.0729
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk32,n=103,97,na,na,33,39,23,22,87,17,16	-1.408 score on a scale	Standard Deviation 1.3855
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-0.546 score on a scale	Standard Deviation 1.1597
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-0.311 score on a scale	Standard Deviation 0.9514
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-0.683 score on a scale	Standard Deviation 1.1231
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk36,n=101,92,na,na,30,30,21,20,84,18,15	-1.271 score on a scale	Standard Deviation 1.4949
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.191 score on a scale	Standard Deviation 0.7331
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk1,n=131,129,130,129,39,35,21,22, 95,17,17	-0.147 score on a scale	Standard Deviation 0.5527
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk40,n=96,90,na,na,28,28,21,19,84,15,17	-1.354 score on a scale	Standard Deviation 1.359
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk48,n=94,88,na,na,28,26,18,19,76,12,14	-1.516 score on a scale	Standard Deviation 1.0635
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-0.666 score on a scale	Standard Deviation 0.9983
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk28,n=115,103,na,na,33,35,21,21,86,17,18	-1.172 score on a scale	Standard Deviation 1.1602
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-0.252 score on a scale	Standard Deviation 0.8116
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk44,n=96,88,na,na,28,27,20,18,84,15,16	-1.168 score on a scale	Standard Deviation 1.2638
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk16,n=126,116,114,128,36,36,21,21,94,15,19	0.128 score on a scale	Standard Deviation 0.8579
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-1.140 score on a scale	Standard Deviation 1.1954
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk1,n=131,129,130,129,39,35,21,22, 95,17,17	-0.141 score on a scale	Standard Deviation 0.7095
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.368 score on a scale	Standard Deviation 0.717
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-0.352 score on a scale	Standard Deviation 0.7471
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-0.312 score on a scale	Standard Deviation 0.9151
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-0.383 score on a scale	Standard Deviation 1.1765
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk16,n=126,116,114,128,36,36,21,21,94,15,19	0.045 score on a scale	Standard Deviation 0.9145
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-0.937 score on a scale	Standard Deviation 1.0966
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk28,n=115,103,na,na,33,35,21,21,86,17,18	-1.244 score on a scale	Standard Deviation 1.2433
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk32,n=103,97,na,na,33,39,23,22,87,17,16	-1.475 score on a scale	Standard Deviation 1.1846
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk36,n=101,92,na,na,30,30,21,20,84,18,15	-1.444 score on a scale	Standard Deviation 1.1949
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk40,n=96,90,na,na,28,28,21,19,84,15,17	-1.494 score on a scale	Standard Deviation 1.3243
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk44,n=96,88,na,na,28,27,20,18,84,15,16	-1.858 score on a scale	Standard Deviation 1.2373
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk48,n=94,88,na,na,28,26,18,19,76,12,14	-1.660 score on a scale	Standard Deviation 1.1805
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk52,n=92,86,na,na,28,26,20,18,79,15,15	-1.690 score on a scale	Standard Deviation 1.2093
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-2.108 score on a scale	Standard Deviation 1.0368
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk44,n=96,88,na,na,28,27,20,18,84,15,16	-2.155 score on a scale	Standard Deviation 0.9488
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-1.403 score on a scale	Standard Deviation 1.206
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk40,n=96,90,na,na,28,28,21,19,84,15,17	-2.315 score on a scale	Standard Deviation 1.0773
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk16,n=126,116,114,128,36,36,21,21,94,15,19	-2.008 score on a scale	Standard Deviation 0.8675
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk48,n=94,88,na,na,28,26,18,19,76,12,14	-2.259 score on a scale	Standard Deviation 1.1813
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk32,n=103,97,na,na,33,39,23,22,87,17,16	-2.363 score on a scale	Standard Deviation 1.0711
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.835 score on a scale	Standard Deviation 0.9466
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk1,n=131,129,130,129,39,35,21,22, 95,17,17	-0.572 score on a scale	Standard Deviation 0.7856
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-2.343 score on a scale	Standard Deviation 1.2649
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk28,n=115,103,na,na,33,35,21,21,86,17,18	-2.117 score on a scale	Standard Deviation 0.8573
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-1.034 score on a scale	Standard Deviation 0.9119
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-1.588 score on a scale	Standard Deviation 0.9714
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk52,n=92,86,na,na,28,26,20,18,79,15,15	-2.070 score on a scale	Standard Deviation 0.9984
Placebo Responder - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk36,n=101,92,na,na,30,30,21,20,84,18,15	-2.269 score on a scale	Standard Deviation 1.0688
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.292 score on a scale	Standard Deviation 0.7448
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk32,n=103,97,na,na,33,39,23,22,87,17,16	-1.875 score on a scale	Standard Deviation 0.9807
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk44,n=96,88,na,na,28,27,20,18,84,15,16	-2.121 score on a scale	Standard Deviation 1.1347
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk16,n=126,116,114,128,36,36,21,21,94,15,19	-1.503 score on a scale	Standard Deviation 0.8746
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-0.613 score on a scale	Standard Deviation 0.9772
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk28,n=115,103,na,na,33,35,21,21,86,17,18	-1.782 score on a scale	Standard Deviation 1.0655
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk52,n=92,86,na,na,28,26,20,18,79,15,15	-2.334 score on a scale	Standard Deviation 1.1428
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-1.330 score on a scale	Standard Deviation 1.4721
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk40,n=96,90,na,na,28,28,21,19,84,15,17	-2.134 score on a scale	Standard Deviation 1.0405
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk36,n=101,92,na,na,30,30,21,20,84,18,15	-1.784 score on a scale	Standard Deviation 0.9029
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-1.399 score on a scale	Standard Deviation 1.1487
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk48,n=94,88,na,na,28,26,18,19,76,12,14	-1.964 score on a scale	Standard Deviation 1.3404
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk1,n=131,129,130,129,39,35,21,22, 95,17,17	-0.235 score on a scale	Standard Deviation 0.7699
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-1.362 score on a scale	Standard Deviation 1.2999
Placebo Responder - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-0.767 score on a scale	Standard Deviation 0.9661
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-1.268 score on a scale	Standard Deviation 1.0533
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk52,n=92,86,na,na,28,26,20,18,79,15,15	-2.676 score on a scale	Standard Deviation 1.3593
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk44,n=96,88,na,na,28,27,20,18,84,15,16	-2.697 score on a scale	Standard Deviation 1.2117
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-2.435 score on a scale	Standard Deviation 1.3266
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.755 score on a scale	Standard Deviation 0.9234
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk16,n=126,116,114,128,36,36,21,21,94,15,19	-2.159 score on a scale	Standard Deviation 1.0767
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk32,n=103,97,na,na,33,39,23,22,87,17,16	-2.629 score on a scale	Standard Deviation 1.3104
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-2.144 score on a scale	Standard Deviation 1.1028
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk36,n=101,92,na,na,30,30,21,20,84,18,15	-2.642 score on a scale	Standard Deviation 1.4305
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk1,n=131,129,130,129,39,35,21,22, 95,17,17	-0.577 score on a scale	Standard Deviation 0.7924
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk48,n=94,88,na,na,28,26,18,19,76,12,14	-2.634 score on a scale	Standard Deviation 1.2189
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk28,n=115,103,na,na,33,35,21,21,86,17,18	-2.470 score on a scale	Standard Deviation 1.2153
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-1.816 score on a scale	Standard Deviation 1.0708
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk40,n=96,90,na,na,28,28,21,19,84,15,17	-2.549 score on a scale	Standard Deviation 1.3305
Abatacept Responders	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-2.317 score on a scale	Standard Deviation 1.2549
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-0.402 score on a scale	Standard Deviation 0.982
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk28,n=115,103,na,na,33,35,21,21,86,17,18	-1.137 score on a scale	Standard Deviation 1.205
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk16,n=126,116,114,128,36,36,21,21,94,15,19	-0.490 score on a scale	Standard Deviation 0.817
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk32,n=103,97,na,na,33,39,23,22,87,17,16	-0.961 score on a scale	Standard Deviation 1.0043
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-0.749 score on a scale	Standard Deviation 1.0757
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk36,n=101,92,na,na,30,30,21,20,84,18,15	-1.200 score on a scale	Standard Deviation 1.3228
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-0.834 score on a scale	Standard Deviation 1.1469
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk40,n=96,90,na,na,28,28,21,19,84,15,17	-1.201 score on a scale	Standard Deviation 1.5293
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-0.595 score on a scale	Standard Deviation 1.116
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk44,n=96,88,na,na,28,27,20,18,84,15,16	-0.881 score on a scale	Standard Deviation 1.3337
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.882 score on a scale	Standard Deviation 0.9526
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk52,n=92,86,na,na,28,26,20,18,79,15,15	-1.390 score on a scale	Standard Deviation 1.1884
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk48,n=94,88,na,na,28,26,18,19,76,12,14	-1.013 score on a scale	Standard Deviation 1.1738
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk1,n=131,129,130,129,39,35,21,22, 95,17,17	-0.361 score on a scale	Standard Deviation 0.3578
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-0.772 score on a scale	Standard Deviation 1.1656
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk4,n=130,131,129,128,39,38,23,21,92,17,19	-0.706 score on a scale	Standard Deviation 0.6999
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk40,n=96,90,na,na,28,28,21,19,84,15,17	-1.612 score on a scale	Standard Deviation 1.1839
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk8,n=130,126,130,130,39,39,23,22,94,17,19	-0.808 score on a scale	Standard Deviation 0.6444
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk24,n=116,108,116,117,37,36,21,22,84,15,18	-0.923 score on a scale	Standard Deviation 1.256
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk48,n=94,88,na,na,28,26,18,19,76,12,14	-1.400 score on a scale	Standard Deviation 1.1985
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk20,n=121,114,,119,125,38,37,23,21,90,16,19	-0.792 score on a scale	Standard Deviation 1.0272
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk36,n=101,92,na,na,30,30,21,20,84,18,15	-1.425 score on a scale	Standard Deviation 0.9247
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk12,n=130,114,123,128,39,37,23,21,93,17,18	-0.945 score on a scale	Standard Deviation 1.1008
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk32,n=103,97,na,na,33,39,23,22,87,17,16	-1.464 score on a scale	Standard Deviation 1.2025
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk52,n=92,86,na,na,28,26,20,18,79,15,15	-0.982 score on a scale	Standard Deviation 1.1943
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk16,n=126,116,114,128,36,36,21,21,94,15,19	-0.322 score on a scale	Standard Deviation 1.0262
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk44,n=96,88,na,na,28,27,20,18,84,15,16	-1.528 score on a scale	Standard Deviation 1.2973
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk2,n=131,127,132,133,39,36,23,21,98,17,18	-0.359 score on a scale	Standard Deviation 0.898
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk1,n=131,129,130,129,39,35,21,22, 95,17,17	-0.222 score on a scale	Standard Deviation 0.7695
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data	Wk28,n=115,103,na,na,33,35,21,21,86,17,18	-0.973 score on a scale	Standard Deviation 1.1034

Secondary

Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM

Time frame: baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24

Population: Participants from the full analysis set were considered for the analysis. For Placebo and Abatacept participants, data collected after treatment switch was treated as missing, as were missing values for all treatment groups

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 1, n=131,129,130,129	-0.89 score on a scale	Standard Error 0.069
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 2, n=131,127,132,133	-0.96 score on a scale	Standard Error 0.08
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 4, n=130,131,138,138	-1.20 score on a scale	Standard Error 0.09
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 8, n=130,126,130,130	-1.21 score on a scale	Standard Error 0.093
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 12, n=130,114,123,128	-1.23 score on a scale	Standard Error 0.097
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 16, n=126,116,114,127	-1.23 score on a scale	Standard Error 0.108
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 20, n=121,114,47,92	-1.44 score on a scale	Standard Error 0.108
AIN457 10mg/kg - 75 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 24, n=116,108,44,84	-1.47 score on a scale	Standard Error 0.115
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 16, n=126,116,114,127	-1.40 score on a scale	Standard Error 0.112
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 12, n=130,114,123,128	-1.36 score on a scale	Standard Error 0.102
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 2, n=131,127,132,133	-0.90 score on a scale	Standard Error 0.081
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 24, n=116,108,44,84	-1.47 score on a scale	Standard Error 0.119
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 20, n=121,114,47,92	-1.49 score on a scale	Standard Error 0.111
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 8, n=130,126,130,130	-1.23 score on a scale	Standard Error 0.094
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 4, n=130,131,138,138	-1.11 score on a scale	Standard Error 0.09
AIN457 10mg/kg - 150 mg	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 1, n=131,129,130,129	-0.73 score on a scale	Standard Error 0.069
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 20, n=121,114,47,92	-0.89 score on a scale	Standard Error 0.146
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 4, n=130,131,138,138	-0.48 score on a scale	Standard Error 0.09
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 8, n=130,126,130,130	-0.61 score on a scale	Standard Error 0.093
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 12, n=130,114,123,128	-0.73 score on a scale	Standard Error 0.1
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 16, n=126,116,114,127	-0.57 score on a scale	Standard Error 0.112
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 24, n=116,108,44,84	-1.02 score on a scale	Standard Error 0.163
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 1, n=131,129,130,129	-0.22 score on a scale	Standard Error 0.069
Placebo	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 2, n=131,127,132,133	-0.35 score on a scale	Standard Error 0.08
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 4, n=130,131,138,138	-1.11 score on a scale	Standard Error 0.091
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 8, n=130,126,130,130	-1.55 score on a scale	Standard Error 0.093
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 2, n=131,127,132,133	-0.78 score on a scale	Standard Error 0.08
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 1, n=131,129,130,129	-0.50 score on a scale	Standard Error 0.069
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 12, n=130,114,123,128	-1.78 score on a scale	Standard Error 0.098
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 24, n=116,108,44,84	-2.07 score on a scale	Standard Error 0.128
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 20, n=121,114,47,92	-1.96 score on a scale	Standard Error 0.117
Abatacept	Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM	week 16, n=126,116,114,127	-1.71 score on a scale	Standard Error 0.108

Secondary

Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data

Blood samples were obtained to monitor disease activity and response to treatment. A negative change from baseline indicates improvement. The ESR results from baseline up to week 52 were based on observed data, i.e. without imputation.

Time frame: baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-14.7 mm/hr	Standard Deviation 20.08
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-13.9 mm/hr	Standard Deviation 23.65
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-16.3 mm/hr	Standard Deviation 20.9
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk52,n=94,91,na,na,29,28,20,18,83,16,16	-17.7 mm/hr	Standard Deviation 21.08
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk2,n=133,130,135,134,39,36,23,22,99,17,18	-12.2 mm/hr	Standard Deviation 19.06
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk48,n=97,92,na,na,28,30,20,19,79,13,14	-17.8 mm/hr	Standard Deviation 23.11
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk44,n=98,93,na,na,28,28,20,19,85,15,16	-18.0 mm/hr	Standard Deviation 21.08
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-12.7 mm/hr	Standard Deviation 22.23
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk40,n=101,96,na,na,29,29,22,20,85,15,17	-18.1 mm/hr	Standard Deviation 21.06
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-15.4 mm/hr	Standard Deviation 20.38
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,87,18,16	-16.6 mm/hr	Standard Deviation 25.2
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk32,n=108,101,na,na,34,32,21,21,88,17,16	-18.3 mm/hr	Standard Deviation 23.51
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk1,n=133,130,131,131,39,36,21,22,97,17,17,	-7.5 mm/hr	Standard Deviation 18.74
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,19	-15.4 mm/hr	Standard Deviation 22.95
AIN457 10mg/kg - 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-16.2 mm/hr	Standard Deviation 21.22
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk40,n=101,96,na,na,29,29,22,20,85,15,17	-17.3 mm/hr	Standard Deviation 21.05
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-17.7 mm/hr	Standard Deviation 19.9
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,19	-16.8 mm/hr	Standard Deviation 23.05
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,87,18,16	-18.4 mm/hr	Standard Deviation 21.51
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-18.4 mm/hr	Standard Deviation 21.18
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-15.7 mm/hr	Standard Deviation 21.62
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk1,n=133,130,131,131,39,36,21,22,97,17,17,	-8.4 mm/hr	Standard Deviation 19.2
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-16.0 mm/hr	Standard Deviation 20.2
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk32,n=108,101,na,na,34,32,21,21,88,17,16	-17.4 mm/hr	Standard Deviation 21.57
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-12.1 mm/hr	Standard Deviation 21.88
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk2,n=133,130,135,134,39,36,23,22,99,17,18	-10.5 mm/hr	Standard Deviation 19.05
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-15.6 mm/hr	Standard Deviation 19.09
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk48,n=97,92,na,na,28,30,20,19,79,13,14	-19.8 mm/hr	Standard Deviation 20.3
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk52,n=94,91,na,na,29,28,20,18,83,16,16	-20.6 mm/hr	Standard Deviation 23.48
AIN457 10mg/kg - 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk44,n=98,93,na,na,28,28,20,19,85,15,16	-16.7 mm/hr	Standard Deviation 23.87
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-9.1 mm/hr	Standard Deviation 26.29
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,19	NA mm/hr	—
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk44,n=98,93,na,na,28,28,20,19,85,15,16	NA mm/hr	—
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-6.5 mm/hr	Standard Deviation 23.48
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-6.0 mm/hr	Standard Deviation 18.9
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk1,n=133,130,131,131,39,36,21,22,97,17,17,	-5.7 mm/hr	Standard Deviation 15.68
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk40,n=101,96,na,na,29,29,22,20,85,15,17	NA mm/hr	—
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,87,18,16	NA mm/hr	—
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-6.4 mm/hr	Standard Deviation 22.72
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-12.0 mm/hr	Standard Deviation 24.31
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk32,n=108,101,na,na,34,32,21,21,88,17,16	NA mm/hr	—
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-5.8 mm/hr	Standard Deviation 21.02
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk52,n=94,91,na,na,29,28,20,18,83,16,16	NA mm/hr	—
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk48,n=97,92,na,na,28,30,20,19,79,13,14	NA mm/hr	—
Placebo	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk2,n=133,130,135,134,39,36,23,22,99,17,18	-5.7 mm/hr	Standard Deviation 18.22
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk52,n=94,91,na,na,29,28,20,18,83,16,16	NA mm/hr	—
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-17.6 mm/hr	Standard Deviation 20.89
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-19.6 mm/hr	Standard Deviation 24.52
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-21.1 mm/hr	Standard Deviation 23.66
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk2,n=133,130,135,134,39,36,23,22,99,17,18	-11.0 mm/hr	Standard Deviation 19.5
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,87,18,16	NA mm/hr	—
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk44,n=98,93,na,na,28,28,20,19,85,15,16	NA mm/hr	—
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-12.6 mm/hr	Standard Deviation 18.14
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk40,n=101,96,na,na,29,29,22,20,85,15,17	NA mm/hr	—
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-19.4 mm/hr	Standard Deviation 20.97
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk32,n=108,101,na,na,34,32,21,21,88,17,16	NA mm/hr	—
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk48,n=97,92,na,na,28,30,20,19,79,13,14	NA mm/hr	—
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk1,n=133,130,131,131,39,36,21,22,97,17,17,	-9.5 mm/hr	Standard Deviation 16.55
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-18.5 mm/hr	Standard Deviation 24.32
Abatacept	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,19	NA mm/hr	—
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-10.8 mm/hr	Standard Deviation 20.33
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk1,n=133,130,131,131,39,36,21,22,97,17,17,	-8.4 mm/hr	Standard Deviation 12.65
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk2,n=133,130,135,134,39,36,23,22,99,17,18	-4.0 mm/hr	Standard Deviation 12.69
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-3.7 mm/hr	Standard Deviation 14.35
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-9.4 mm/hr	Standard Deviation 19.24
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-5.9 mm/hr	Standard Deviation 17.96
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-3.1 mm/hr	Standard Deviation 19.21
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-21.1 mm/hr	Standard Deviation 23.66
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,19	-17.9 mm/hr	Standard Deviation 24.87
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk32,n=108,101,na,na,34,32,21,21,88,17,16	-17.2 mm/hr	Standard Deviation 16.7
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,87,18,16	-17.8 mm/hr	Standard Deviation 21.72
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk40,n=101,96,na,na,29,29,22,20,85,15,17	-20.6 mm/hr	Standard Deviation 19.66
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk44,n=98,93,na,na,28,28,20,19,85,15,16	-20.1 mm/hr	Standard Deviation 17.61
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk48,n=97,92,na,na,28,30,20,19,79,13,14	-20.8 mm/hr	Standard Deviation 18.26
Placebo Non-responder - AIN457 75 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk52,n=94,91,na,na,29,28,20,18,83,16,16	-14.9 mm/hr	Standard Deviation 20.53
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk32,n=108,101,na,na,34,32,21,21,88,17,16	-12.8 mm/hr	Standard Deviation 26.21
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,87,18,16	-13.4 mm/hr	Standard Deviation 29.49
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-0.9 mm/hr	Standard Deviation 27.25
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk2,n=133,130,135,134,39,36,23,22,99,17,18	-5.6 mm/hr	Standard Deviation 26.44
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk48,n=97,92,na,na,28,30,20,19,79,13,14	-7.2 mm/hr	Standard Deviation 22.58
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-10.5 mm/hr	Standard Deviation 20.08
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-1.5 mm/hr	Standard Deviation 25.62
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk1,n=133,130,131,131,39,36,21,22,97,17,17,	-1.1 mm/hr	Standard Deviation 18.88
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,19	-12.5 mm/hr	Standard Deviation 30.87
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-14.7 mm/hr	Standard Deviation 27.77
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk40,n=101,96,na,na,29,29,22,20,85,15,17	-12.3 mm/hr	Standard Deviation 26.37
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-1.1 mm/hr	Standard Deviation 25.47
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-3.8 mm/hr	Standard Deviation 20.5
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk44,n=98,93,na,na,28,28,20,19,85,15,16	-16.0 mm/hr	Standard Deviation 25.3
Placebo Non-responder - AIN457 150 mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk52,n=94,91,na,na,29,28,20,18,83,16,16	-15.1 mm/hr	Standard Deviation 21.5
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-11.2 mm/hr	Standard Deviation 18.06
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk32,n=108,101,na,na,34,32,21,21,88,17,16	-16.8 mm/hr	Standard Deviation 24.37
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk48,n=97,92,na,na,28,30,20,19,79,13,14	-12.2 mm/hr	Standard Deviation 29.55
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,87,18,16	-17.3 mm/hr	Standard Deviation 22.02
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-8.2 mm/hr	Standard Deviation 24.09
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk1,n=133,130,131,131,39,36,21,22,97,17,17,	-5.7 mm/hr	Standard Deviation 14.97
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-7.4 mm/hr	Standard Deviation 29.4
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk2,n=133,130,135,134,39,36,23,22,99,17,18	-9.7 mm/hr	Standard Deviation 17.86
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-16.1 mm/hr	Standard Deviation 21.57
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk52,n=94,91,na,na,29,28,20,18,83,16,16	-14.4 mm/hr	Standard Deviation 24.54
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-9.3 mm/hr	Standard Deviation 13.81
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk40,n=101,96,na,na,29,29,22,20,85,15,17	-13.3 mm/hr	Standard Deviation 18.78
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-17.6 mm/hr	Standard Deviation 23.03
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,19	-12.3 mm/hr	Standard Deviation 24.1
Placebo Responder - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk44,n=98,93,na,na,28,28,20,19,85,15,16	-12.0 mm/hr	Standard Deviation 29.2
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-5.5 mm/hr	Standard Deviation 20.06
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk44,n=98,93,na,na,28,28,20,19,85,15,16	-19.2 mm/hr	Standard Deviation 22.57
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-5.5 mm/hr	Standard Deviation 27.07
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk2,n=133,130,135,134,39,36,23,22,99,17,18	-6.6 mm/hr	Standard Deviation 14.44
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-4.9 mm/hr	Standard Deviation 20.54
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,19	-14.6 mm/hr	Standard Deviation 17.31
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-8.3 mm/hr	Standard Deviation 14.29
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk32,n=108,101,na,na,34,32,21,21,88,17,16	-14.1 mm/hr	Standard Deviation 20.72
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk1,n=133,130,131,131,39,36,21,22,97,17,17,	-7.1 mm/hr	Standard Deviation 13.22
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-11.6 mm/hr	Standard Deviation 34.23
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,87,18,16	-16.5 mm/hr	Standard Deviation 17.95
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-8.2 mm/hr	Standard Deviation 23.89
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk52,n=94,91,na,na,29,28,20,18,83,16,16	-13.6 mm/hr	Standard Deviation 27.16
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk40,n=101,96,na,na,29,29,22,20,85,15,17	-16.4 mm/hr	Standard Deviation 21.79
Placebo Responder - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk48,n=97,92,na,na,28,30,20,19,79,13,14	-19.4 mm/hr	Standard Deviation 20.58
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-19.9 mm/hr	Standard Deviation 21.08
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk1,n=133,130,131,131,39,36,21,22,97,17,17,	-10.2 mm/hr	Standard Deviation 17.11
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk48,n=97,92,na,na,28,30,20,19,79,13,14	-23.9 mm/hr	Standard Deviation 25.56
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-18.3 mm/hr	Standard Deviation 21.56
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-21.1 mm/hr	Standard Deviation 24.73
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk2,n=133,130,135,134,39,36,23,22,99,17,18	-10.2 mm/hr	Standard Deviation 20.33
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,19	-22.4 mm/hr	Standard Deviation 22.9
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-21.1 mm/hr	Standard Deviation 24.62
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk52,n=94,91,na,na,29,28,20,18,83,16,16	-25.2 mm/hr	Standard Deviation 27.88
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk40,n=101,96,na,na,29,29,22,20,85,15,17	-22.2 mm/hr	Standard Deviation 26.24
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-12.3 mm/hr	Standard Deviation 18.66
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-7.0 mm/hr	Standard Deviation 22.32
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk32,n=108,101,na,na,34,32,21,21,88,17,16	-25.5 mm/hr	Standard Deviation 24.89
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk44,n=98,93,na,na,28,28,20,19,85,15,16	-24.9 mm/hr	Standard Deviation 25.66
Abatacept Responders	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,87,18,16	-21.7 mm/hr	Standard Deviation 25.4
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk32,n=108,101,na,na,34,32,21,21,88,17,16	-25.7 mm/hr	Standard Deviation 21.14
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-22.0 mm/hr	Standard Deviation 23.6
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-18.4 mm/hr	Standard Deviation 23.07
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-20.7 mm/hr	Standard Deviation 20.65
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,19	-26.1 mm/hr	Standard Deviation 19.83
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-13.9 mm/hr	Standard Deviation 23.29
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-15.8 mm/hr	Standard Deviation 17.49
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,87,18,16	-26.0 mm/hr	Standard Deviation 21.21
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk40,n=101,96,na,na,29,29,22,20,85,15,17	-23.8 mm/hr	Standard Deviation 22.96
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk2,n=133,130,135,134,39,36,23,22,99,17,18	-12.5 mm/hr	Standard Deviation 16.71
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk44,n=98,93,na,na,28,28,20,19,85,15,16	-22.3 mm/hr	Standard Deviation 23.36
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk1,n=133,130,131,131,39,36,21,22,97,17,17,	-7.7 mm/hr	Standard Deviation 13.9
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk52,n=94,91,na,na,29,28,20,18,83,16,16	-27.4 mm/hr	Standard Deviation 22.71
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk48,n=97,92,na,na,28,30,20,19,79,13,14	-18.9 mm/hr	Standard Deviation 26.41
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-14.9 mm/hr	Standard Deviation 17.78
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk2,n=133,130,135,134,39,36,23,22,99,17,18	-13.6 mm/hr	Standard Deviation 17.78
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk40,n=101,96,na,na,29,29,22,20,85,15,17	-22.9 mm/hr	Standard Deviation 15.57
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk12,n=133,118,127,131,39,39,23,21,96,17,18	-17.9 mm/hr	Standard Deviation 19.31
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk48,n=97,92,na,na,28,30,20,19,79,13,14	-20.2 mm/hr	Standard Deviation 18.16
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,87,18,16	-16.6 mm/hr	Standard Deviation 23.31
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk4,n=133,135,131,133,39,39,23,21,97,17,19	-11.3 mm/hr	Standard Deviation 16.46
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk32,n=108,101,na,na,34,32,21,21,88,17,16	-23.1 mm/hr	Standard Deviation 21.46
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk16,n=129,121,122,130,36,38,21,22,95,16,19	-8.8 mm/hr	Standard Deviation 25.22
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk20,n=123,116,120,127,38,37,23,21,91,17,19	-20.5 mm/hr	Standard Deviation 22.81
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,19	-17.4 mm/hr	Standard Deviation 24.77
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk52,n=94,91,na,na,29,28,20,18,83,16,16	-15.4 mm/hr	Standard Deviation 22.53
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk8,n=133,129,131,132,39,39,23,22,96,17,19	-17.6 mm/hr	Standard Deviation 15.03
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk24,n=122,113,117,123,38,36,21,22,88,17,18	-11.4 mm/hr	Standard Deviation 26.96
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk1,n=133,130,131,131,39,36,21,22,97,17,17,	-7.2 mm/hr	Standard Deviation 16.3
Abatacept Non-responders - AIN457 150mg	Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data	Wk44,n=98,93,na,na,28,28,20,19,85,15,16	-18.5 mm/hr	Standard Deviation 21

Secondary

Change From Baseline in HAQ-DI - Observed Data

The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, are you able to... perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement. The HAQ-DI results from baseline up to week 52 were based on observed data, i.e. without imputation.

Time frame: baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Arm	Measure	Group	Value (MEAN)	Dispersion
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk8,n=132,127,131,130,39,39,23,22,94,17,19	-0.277 score on a scale	Standard Deviation 0.5062
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk44,n=97,90,na,na,28,27,20,18,84,15,16	-0.331 score on a scale	Standard Deviation 0.5871
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk4,n=133,133,131,130,39,39,23,21,94,17,19	-0.299 score on a scale	Standard Deviation 0.4551
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk48,n-94,89,na,na,28,26,19,19,76,12,14	-0.303 score on a scale	Standard Deviation 0.5062
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.333 score on a scale	Standard Deviation 0.5111
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk32,n=104,97,na,na,33,30,21,19,87,17,17	-0.358 score on a scale	Standard Deviation 0.4964
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.294 score on a scale	Standard Deviation 0.5236
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	wk1,n=132,129,130,129,39,35,21,22,95,17,17	-0.225 score on a scale	Standard Deviation 0.3766
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	-0.339 score on a scale	Standard Deviation 0.5687
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk24,n=117,110,117,120,38,36,21,22,86,16,18	-0.268 score on a scale	Standard Deviation 0.493
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk52,n=92,87,na,na,28,26,20,18,79,15,15	-0.341 score on a scale	Standard Deviation 0.5428
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18	-0.215 score on a scale	Standard Deviation 0.3877
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk28,n=115,102,na,na,33,35,21,21,86,17,19	-0.304 score on a scale	Standard Deviation 0.5342
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.287 score on a scale	Standard Deviation 0.5384
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk40,n=96,89,na,na,28,28,21,19,84,15,17	-0.424 score on a scale	Standard Deviation 0.5967
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk28,n=115,102,na,na,33,35,21,21,86,17,19	-0.439 score on a scale	Standard Deviation 0.578
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk24,n=117,110,117,120,38,36,21,22,86,16,18	-0.405 score on a scale	Standard Deviation 0.5767
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk52,n=92,87,na,na,28,26,20,18,79,15,15	-0.516 score on a scale	Standard Deviation 0.6036
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18	-0.239 score on a scale	Standard Deviation 0.4885
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk48,n-94,89,na,na,28,26,19,19,76,12,14	-0.483 score on a scale	Standard Deviation 0.5459
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk4,n=133,133,131,130,39,39,23,21,94,17,19	-0.300 score on a scale	Standard Deviation 0.5184
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk44,n=97,90,na,na,28,27,20,18,84,15,16	-0.449 score on a scale	Standard Deviation 0.5427
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk8,n=132,127,131,130,39,39,23,22,94,17,19	-0.309 score on a scale	Standard Deviation 0.5175
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk40,n=96,89,na,na,28,28,21,19,84,15,17	-0.440 score on a scale	Standard Deviation 0.5416
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.307 score on a scale	Standard Deviation 0.5488
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	wk1,n=132,129,130,129,39,35,21,22,95,17,17	-0.215 score on a scale	Standard Deviation 0.4095
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	-0.430 score on a scale	Standard Deviation 0.5573
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.355 score on a scale	Standard Deviation 0.6217
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk32,n=104,97,na,na,33,30,21,19,87,17,17	-0.505 score on a scale	Standard Deviation 0.5759
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.402 score on a scale	Standard Deviation 0.6429
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk48,n-94,89,na,na,28,26,19,19,76,12,14	NA score on a scale	—
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk24,n=117,110,117,120,38,36,21,22,86,16,18	0.346 score on a scale	Standard Deviation 0.5941
Placebo	Change From Baseline in HAQ-DI - Observed Data	wk1,n=132,129,130,129,39,35,21,22,95,17,17	-0.101 score on a scale	Standard Deviation 0.3186
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk28,n=115,102,na,na,33,35,21,21,86,17,19	NA score on a scale	—
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk8,n=132,127,131,130,39,39,23,22,94,17,19	-0.217 score on a scale	Standard Deviation 0.5457
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk40,n=96,89,na,na,28,28,21,19,84,15,17	NA score on a scale	—
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.319 score on a scale	Standard Deviation 0.5637
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18	-0.191 score on a scale	Standard Deviation 0.434
Placebo	Change From Baseline in HAQ-DI - Observed Data	wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.241 score on a scale	Standard Deviation 0.5152
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	NA score on a scale	—
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk52,n=92,87,na,na,28,26,20,18,79,15,15	NA score on a scale	—
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.279 score on a scale	Standard Deviation 0.5493
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk32,n=104,97,na,na,33,30,21,19,87,17,17	NA score on a scale	—
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk44,n=97,90,na,na,28,27,20,18,84,15,16	NA score on a scale	—
Placebo	Change From Baseline in HAQ-DI - Observed Data	Wk4,n=133,133,131,130,39,39,23,21,94,17,19	-0.214 score on a scale	Standard Deviation 0.4492
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk52,n=92,87,na,na,28,26,20,18,79,15,15	NA score on a scale	—
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk4,n=133,133,131,130,39,39,23,21,94,17,19	-0.368 score on a scale	Standard Deviation 0.513
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk32,n=104,97,na,na,33,30,21,19,87,17,17	NA score on a scale	—
Abatacept	Change From Baseline in HAQ-DI - Observed Data	wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.508 score on a scale	Standard Deviation 0.6369
Abatacept	Change From Baseline in HAQ-DI - Observed Data	wk1,n=132,129,130,129,39,35,21,22,95,17,17	-0.194 score on a scale	Standard Deviation 0.429
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk24,n=117,110,117,120,38,36,21,22,86,16,18	-0.590 score on a scale	Standard Deviation 0.6872
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk8,n=132,127,131,130,39,39,23,22,94,17,19	-0.463 score on a scale	Standard Deviation 0.5182
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	NA score on a scale	—
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.535 score on a scale	Standard Deviation 0.6418
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk44,n=97,90,na,na,28,27,20,18,84,15,16	NA score on a scale	—
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk40,n=96,89,na,na,28,28,21,19,84,15,17	NA score on a scale	—
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk28,n=115,102,na,na,33,35,21,21,86,17,19	NA score on a scale	—
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk48,n-94,89,na,na,28,26,19,19,76,12,14	NA score on a scale	—
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18	-0.254 score on a scale	Standard Deviation 0.452
Abatacept	Change From Baseline in HAQ-DI - Observed Data	Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.583 score on a scale	Standard Deviation 0.6654
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk48,n-94,89,na,na,28,26,19,19,76,12,14	-0.348 score on a scale	Standard Deviation 0.5886
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.109 score on a scale	Standard Deviation 0.4783
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.237 score on a scale	Standard Deviation 0.4756
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	-0.368 score on a scale	Standard Deviation 0.5397
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk24,n=117,110,117,120,38,36,21,22,86,16,18	-0.257 score on a scale	Standard Deviation 0.473
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk28,n=115,102,na,na,33,35,21,21,86,17,19	-0.345 score on a scale	Standard Deviation 0.588
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk4,n=133,133,131,130,39,39,23,21,94,17,19	-0.077 score on a scale	Standard Deviation 0.3634
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.167 score on a scale	Standard Deviation 0.5295
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk52,n=92,87,na,na,28,26,20,18,79,15,15	-0.402 score on a scale	Standard Deviation 0.5436
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk32,n=104,97,na,na,33,30,21,19,87,17,17	-0.284 score on a scale	Standard Deviation 0.4627
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18	-0.122 score on a scale	Standard Deviation 0.2605
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk44,n=97,90,na,na,28,27,20,18,84,15,16	-0.277 score on a scale	Standard Deviation 0.6377
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk8,n=132,127,131,130,39,39,23,22,94,17,19	-0.186 score on a scale	Standard Deviation 0.5097
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	wk1,n=132,129,130,129,39,35,21,22,95,17,17	-0.119 score on a scale	Standard Deviation 0.2896
Placebo Non-responder - AIN457 75 mg	Change From Baseline in HAQ-DI - Observed Data	Wk40,n=96,89,na,na,28,28,21,19,84,15,17	-0.522 score on a scale	Standard Deviation 0.6805
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk24,n=117,110,117,120,38,36,21,22,86,16,18	-0.253 score on a scale	Standard Deviation 0.6502
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	wk1,n=132,129,130,129,39,35,21,22,95,17,17	-0.079 score on a scale	Standard Deviation 0.3093
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18	-0.176 score on a scale	Standard Deviation 0.4631
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk4,n=133,133,131,130,39,39,23,21,94,17,19	-0.224 score on a scale	Standard Deviation 0.4968
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk8,n=132,127,131,130,39,39,23,22,94,17,19	-0.128 score on a scale	Standard Deviation 0.5077
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.179 score on a scale	Standard Deviation 0.5133
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.111 score on a scale	Standard Deviation 0.4591
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.179 score on a scale	Standard Deviation 0.5158
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk28,n=115,102,na,na,33,35,21,21,86,17,19	-0.336 score on a scale	Standard Deviation 0.5846
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk32,n=104,97,na,na,33,30,21,19,87,17,17	-0.300 score on a scale	Standard Deviation 0.5039
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	-0.383 score on a scale	Standard Deviation 0.45
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk40,n=96,89,na,na,28,28,21,19,84,15,17	-0.391 score on a scale	Standard Deviation 0.5446
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk44,n=97,90,na,na,28,27,20,18,84,15,16	-0.523 score on a scale	Standard Deviation 0.6587
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk48,n-94,89,na,na,28,26,19,19,76,12,14	-0.413 score on a scale	Standard Deviation 0.5698
Placebo Non-responder - AIN457 150 mg	Change From Baseline in HAQ-DI - Observed Data	Wk52,n=92,87,na,na,28,26,20,18,79,15,15	-0.351 score on a scale	Standard Deviation 0.6335
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.543 score on a scale	Standard Deviation 0.5325
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk4,n=133,133,131,130,39,39,23,21,94,17,19	-0.364 score on a scale	Standard Deviation 0.5627
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk8,n=132,127,131,130,39,39,23,22,94,17,19	-0.543 score on a scale	Standard Deviation 0.6313
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk40,n=96,89,na,na,28,28,21,19,84,15,17	-0.571 score on a scale	Standard Deviation 0.5736
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.565 score on a scale	Standard Deviation 0.5356
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk48,n-94,89,na,na,28,26,19,19,76,12,14	-0.605 score on a scale	Standard Deviation 0.6113
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk32,n=104,97,na,na,33,30,21,19,87,17,17	-0.679 score on a scale	Standard Deviation 0.5414
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk44,n=97,90,na,na,28,27,20,18,84,15,16	-0.638 score on a scale	Standard Deviation 0.5144
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	wk1,n=132,129,130,129,39,35,21,22,95,17,17	-0.125 score on a scale	Standard Deviation 0.4257
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk24,n=117,110,117,120,38,36,21,22,86,16,18	-0.589 score on a scale	Standard Deviation 0.5648
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk28,n=115,102,na,na,33,35,21,21,86,17,19	-0.625 score on a scale	Standard Deviation 0.4809
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18	-0.380 score on a scale	Standard Deviation 0.5063
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.451 score on a scale	Standard Deviation 0.6167
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk52,n=92,87,na,na,28,26,20,18,79,15,15	-0.606 score on a scale	Standard Deviation 0.6492
Placebo Responder - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	-0.607 score on a scale	Standard Deviation 0.5538
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18	-0.250 score on a scale	Standard Deviation 0.5015
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk44,n=97,90,na,na,28,27,20,18,84,15,16	-0.514 score on a scale	Standard Deviation 0.7752
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk32,n=104,97,na,na,33,30,21,19,87,17,17	-0.546 score on a scale	Standard Deviation 0.5998
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.472 score on a scale	Standard Deviation 0.5988
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk8,n=132,127,131,130,39,39,23,22,94,17,19	-0.176 score on a scale	Standard Deviation 0.4782
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk28,n=115,102,na,na,33,35,21,21,86,17,19	-0.601 score on a scale	Standard Deviation 0.5571
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk52,n=92,87,na,na,28,26,20,18,79,15,15	-0.569 score on a scale	Standard Deviation 0.7126
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.381 score on a scale	Standard Deviation 0.3982
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk40,n=96,89,na,na,28,28,21,19,84,15,17	-0.539 score on a scale	Standard Deviation 0.6998
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	-0.474 score on a scale	Standard Deviation 0.6032
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.470 score on a scale	Standard Deviation 0.7309
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk48,n-94,89,na,na,28,26,19,19,76,12,14	-0.454 score on a scale	Standard Deviation 0.5547
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	wk1,n=132,129,130,129,39,35,21,22,95,17,17	-0.153 score on a scale	Standard Deviation 0.2468
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk24,n=117,110,117,120,38,36,21,22,86,16,18	-0.420 score on a scale	Standard Deviation 0.6732
Placebo Responder - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk4,n=133,133,131,130,39,39,23,21,94,17,19	-0.310 score on a scale	Standard Deviation 0.3103
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk4,n=133,133,131,130,39,39,23,21,94,17,19	-0.445 score on a scale	Standard Deviation 0.5245
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk52,n=92,87,na,na,28,26,20,18,79,15,15	-0.788 score on a scale	Standard Deviation 0.6853
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk44,n=97,90,na,na,28,27,20,18,84,15,16	-0.781 score on a scale	Standard Deviation 0.7252
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk24,n=117,110,117,120,38,36,21,22,86,16,18	-0.744 score on a scale	Standard Deviation 0.6787
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18	-0.300 score on a scale	Standard Deviation 0.4693
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.660 score on a scale	Standard Deviation 0.659
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk32,n=104,97,na,na,33,30,21,19,87,17,17	-0.741 score on a scale	Standard Deviation 0.6909
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.622 score on a scale	Standard Deviation 0.652
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	-0.756 score on a scale	Standard Deviation 0.6844
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	wk1,n=132,129,130,129,39,35,21,22,95,17,17	-0.232 score on a scale	Standard Deviation 0.4551
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk48,n-94,89,na,na,28,26,19,19,76,12,14	-0.798 score on a scale	Standard Deviation 0.6481
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk28,n=115,102,na,na,33,35,21,21,86,17,19	-0.689 score on a scale	Standard Deviation 0.6428
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk8,n=132,127,131,130,39,39,23,22,94,17,19	-0.543 score on a scale	Standard Deviation 0.5289
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk40,n=96,89,na,na,28,28,21,19,84,15,17	-0.763 score on a scale	Standard Deviation 0.675
Abatacept Responders	Change From Baseline in HAQ-DI - Observed Data	Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.699 score on a scale	Standard Deviation 0.6849
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.086 score on a scale	Standard Deviation 0.3972
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk28,n=115,102,na,na,33,35,21,21,86,17,19	-0.309 score on a scale	Standard Deviation 0.5522
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.195 score on a scale	Standard Deviation 0.4281
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk32,n=104,97,na,na,33,30,21,19,87,17,17	-0.228 score on a scale	Standard Deviation 0.5612
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.221 score on a scale	Standard Deviation 0.4274
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	-0.285 score on a scale	Standard Deviation 0.5891
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk8,n=132,127,131,130,39,39,23,22,94,17,19	-0.206 score on a scale	Standard Deviation 0.49
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk40,n=96,89,na,na,28,28,21,19,84,15,17	-0.242 score on a scale	Standard Deviation 0.6312
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk4,n=133,133,131,130,39,39,23,21,94,17,19	-0.110 score on a scale	Standard Deviation 0.3505
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk44,n=97,90,na,na,28,27,20,18,84,15,16	-0.308 score on a scale	Standard Deviation 0.6319
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18	-0.132 score on a scale	Standard Deviation 0.363
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk52,n=92,87,na,na,28,26,20,18,79,15,15	-0.392 score on a scale	Standard Deviation 0.5216
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk48,n-94,89,na,na,28,26,19,19,76,12,14	-0.229 score on a scale	Standard Deviation 0.6546
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	wk1,n=132,129,130,129,39,35,21,22,95,17,17	-0.081 score on a scale	Standard Deviation 0.3616
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in HAQ-DI - Observed Data	Wk24,n=117,110,117,120,38,36,21,22,86,16,18	-0.180 score on a scale	Standard Deviation 0.4257
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk40,n=96,89,na,na,28,28,21,19,84,15,17	-0.390 score on a scale	Standard Deviation 0.6523
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk8,n=132,127,131,130,39,39,23,22,94,17,19	-0.303 score on a scale	Standard Deviation 0.378
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk24,n=117,110,117,120,38,36,21,22,86,16,18	-0.215 score on a scale	Standard Deviation 0.6443
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk48,n-94,89,na,na,28,26,19,19,76,12,14	-0.286 score on a scale	Standard Deviation 0.7618
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	wk1,n=132,129,130,129,39,35,21,22,95,17,17	-0.096 score on a scale	Standard Deviation 0.3047
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk20,n=122,114,119,125,38,37,23,21,90,16,19	-0.454 score on a scale	Standard Deviation 0.5436
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk36,n=102,93,na,na,30,30,21,19,84,18,16,	-0.430 score on a scale	Standard Deviation 0.6723
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	wk12,n=130,114,123,129,39,37,23,21,94,17,18	-0.181 score on a scale	Standard Deviation 0.5376
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk32,n=104,97,na,na,33,30,21,19,87,17,17	-0.375 score on a scale	Standard Deviation 0.7315
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk52,n=92,87,na,na,28,26,20,18,79,15,15	-0.258 score on a scale	Standard Deviation 0.8298
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk16,n=127,118,116,129,36,37,21,22,94,16,19	-0.204 score on a scale	Standard Deviation 0.4827
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18	-0.118 score on a scale	Standard Deviation 0.3987
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk44,n=97,90,na,na,28,27,20,18,84,15,16	-0.203 score on a scale	Standard Deviation 0.7917
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk28,n=115,102,na,na,33,35,21,21,86,17,19	-0.303 score on a scale	Standard Deviation 0.5882
Abatacept Non-responders - AIN457 150mg	Change From Baseline in HAQ-DI - Observed Data	Wk4,n=133,133,131,130,39,39,23,21,94,17,19	-0.217 score on a scale	Standard Deviation 0.4874

Secondary

Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)

The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, are you able to... perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.

Time frame: baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24

Population: Participants from the full analysis set were considered for this analysis. For Placebo and Abatacept participants, data collected after treatment switch was treated as missing, as were missing values for all treatment groups.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 1, n=132,129,130,129	-0.22 score on a scale	Standard Error 0.032
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 2, n=131,130,134,133	-0.22 score on a scale	Standard Error 0.036
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 4, n=133,133,131,130	-0.30 score on a scale	Standard Error 0.039
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 8, n=132,127,131,130	-0.29 score on a scale	Standard Error 0.042
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 12, n=130,114,123,129	-0.31 score on a scale	Standard Error 0.046
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 16, n=127,118,116,129	-0.30 score on a scale	Standard Error 0.048
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 20, n=122,114,47,92	-0.36 score on a scale	Standard Error 0.051
AIN457 10mg/kg - 75 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 24, n=117,110,44,86	-0.30 score on a scale	Standard Error 0.049
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 16, n=127,118,116,129	-0.37 score on a scale	Standard Error 0.049
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 12, n=130,114,123,129	-0.33 score on a scale	Standard Error 0.047
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 2, n=131,130,134,133	-0.25 score on a scale	Standard Error 0.036
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 24, n=117,110,44,86	-0.39 score on a scale	Standard Error 0.051
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 20, n=122,114,47,92	-0.42 score on a scale	Standard Error 0.052
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 8, n=132,127,131,130	-0.32 score on a scale	Standard Error 0.043
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 4, n=133,133,131,130	-0.31 score on a scale	Standard Error 0.04
AIN457 10mg/kg - 150 mg	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 1, n=132,129,130,129	-0.21 score on a scale	Standard Error 0.032
Placebo	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 20, n=122,114,47,92	-0.21 score on a scale	Standard Error 0.066
Placebo	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 4, n=133,133,131,130	-0.17 score on a scale	Standard Error 0.04
Placebo	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 8, n=132,127,131,130	-0.17 score on a scale	Standard Error 0.043
Placebo	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 12, n=130,114,123,129	-0.18 score on a scale	Standard Error 0.047
Placebo	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 16, n=127,118,116,129	-0.22 score on a scale	Standard Error 0.049
Placebo	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 24, n=117,110,44,86	-0.26 score on a scale	Standard Error 0.065
Placebo	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 1, n=132,129,130,129	-0.08 score on a scale	Standard Error 0.032
Placebo	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 2, n=131,130,134,133	-0.16 score on a scale	Standard Error 0.036
Abatacept	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 4, n=133,133,131,130	-0.36 score on a scale	Standard Error 0.04
Abatacept	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 8, n=132,127,131,130	-0.46 score on a scale	Standard Error 0.043
Abatacept	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 2, n=131,130,134,133	-0.26 score on a scale	Standard Error 0.036
Abatacept	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 1, n=132,129,130,129	-0.19 score on a scale	Standard Error 0.032
Abatacept	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 12, n=130,114,123,129	-0.51 score on a scale	Standard Error 0.046
Abatacept	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 24, n=117,110,44,86	-0.61 score on a scale	Standard Error 0.053
Abatacept	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 20, n=122,114,47,92	-0.57 score on a scale	Standard Error 0.054
Abatacept	Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)	week 16, n=127,118,116,129	-0.52 score on a scale	Standard Error 0.048

Secondary

Change From Baseline in hsCRP - Observed Data

Blood samples were obtained to identify the presence of inflammation, to determine its severity and to monitor response to treatment. A negative change from baseline indicates improvement. The hsCRP results from baseline up to week 52 were based on observed data, i.e. without imputation.

Time frame: baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

Arm	Measure	Group	Value (MEAN)	Dispersion
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-10.18 mg/L	Standard Deviation 33.4
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,85,18,15	-6.60 mg/L	Standard Deviation 25.895
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	-6.59 mg/L	Standard Deviation 20.975
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-10.91 mg/L	Standard Deviation 30.815
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk24,n=121,113,116,120,37,36,21,22,86,16,18	-6.90 mg/L	Standard Deviation 22.098
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,18	-4.94 mg/L	Standard Deviation 23.155
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk52,n=95,92,na,na,29,28,20,18,83,16,16	-6.68 mg/L	Standard Deviation 26.24
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk4,n=131,134,129,133,39,38,23,21,97,17,19	-9.10 mg/L	Standard Deviation 20.514
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk2,n=133,129,133,135,39,36,23,21,100,17,18	-10.24 mg/L	Standard Deviation 33.209
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk32,n=107,101,na,na,34,32,20,21,87,17,16	-8.57 mg/L	Standard Deviation 20.826
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk16,n=129,120,121,131,36,38,21,21,96,16,19	-9.97 mg/L	Standard Deviation 33.291
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-9.19 mg/L	Standard Deviation 32.876
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk12,n=133,119,128,131,39,39,23,22,96,17,18	-9.41 mg/L	Standard Deviation 31.859
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	Wk48,n=97,91,na,na,28,29,20,19,79,13,14	-6.19 mg/L	Standard Deviation 18.912
AIN457 10mg/kg - 75 mg	Change From Baseline in hsCRP - Observed Data	WK40,n=101,96,na,na,29,29,22,20,86,15,17	-8.74 mg/L	Standard Deviation 22.257
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk32,n=107,101,na,na,34,32,20,21,87,17,16	7.37 mg/L	Standard Deviation 24.564
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	-7.25 mg/L	Standard Deviation 24.681
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-12.94 mg/L	Standard Deviation 30.854
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	WK40,n=101,96,na,na,29,29,22,20,86,15,17	-7.09 mg/L	Standard Deviation 24.325
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk52,n=95,92,na,na,29,28,20,18,83,16,16	-8.14 mg/L	Standard Deviation 22.149
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk2,n=133,129,133,135,39,36,23,21,100,17,18	-11.51 mg/L	Standard Deviation 32.139
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk24,n=121,113,116,120,37,36,21,22,86,16,18	-4.92 mg/L	Standard Deviation 23.075
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk12,n=133,119,128,131,39,39,23,22,96,17,18	-9.66 mg/L	Standard Deviation 24.298
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-10.31 mg/L	Standard Deviation 27.754
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk16,n=129,120,121,131,36,38,21,21,96,16,19	-5.78 mg/L	Standard Deviation 25.418
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,18	-5.87 mg/L	Standard Deviation 25.885
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk48,n=97,91,na,na,28,29,20,19,79,13,14	-7.63 mg/L	Standard Deviation 21.682
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk4,n=131,134,129,133,39,38,23,21,97,17,19	-10.76 mg/L	Standard Deviation 33.376
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,85,18,15	-6.36 mg/L	Standard Deviation 22.571
AIN457 10mg/kg - 150 mg	Change From Baseline in hsCRP - Observed Data	Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-8.05 mg/L	Standard Deviation 22.394
Placebo	Change From Baseline in hsCRP - Observed Data	Wk12,n=133,119,128,131,39,39,23,22,96,17,18	-0.69 mg/L	Standard Deviation 18.908
Placebo	Change From Baseline in hsCRP - Observed Data	Wk24,n=121,113,116,120,37,36,21,22,86,16,18	-6.88 mg/L	Standard Deviation 21.014
Placebo	Change From Baseline in hsCRP - Observed Data	Wk52,n=95,92,na,na,29,28,20,18,83,16,16	NA mg/L	—
Placebo	Change From Baseline in hsCRP - Observed Data	Wk2,n=133,129,133,135,39,36,23,21,100,17,18	-2.21 mg/L	Standard Deviation 14.501
Placebo	Change From Baseline in hsCRP - Observed Data	Wk48,n=97,91,na,na,28,29,20,19,79,13,14	NA mg/L	—
Placebo	Change From Baseline in hsCRP - Observed Data	Wk4,n=131,134,129,133,39,38,23,21,97,17,19	-1.53 mg/L	Standard Deviation 19.311
Placebo	Change From Baseline in hsCRP - Observed Data	Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-0.69 mg/L	Standard Deviation 15.521
Placebo	Change From Baseline in hsCRP - Observed Data	Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	NA mg/L	—
Placebo	Change From Baseline in hsCRP - Observed Data	Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-2.94 mg/L	Standard Deviation 20.601
Placebo	Change From Baseline in hsCRP - Observed Data	WK40,n=101,96,na,na,29,29,22,20,86,15,17	NA mg/L	—
Placebo	Change From Baseline in hsCRP - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,18	NA mg/L	—
Placebo	Change From Baseline in hsCRP - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,85,18,15	NA mg/L	—
Placebo	Change From Baseline in hsCRP - Observed Data	Wk16,n=129,120,121,131,36,38,21,21,96,16,19	-1.82 mg/L	Standard Deviation 20.849
Placebo	Change From Baseline in hsCRP - Observed Data	Wk32,n=107,101,na,na,34,32,20,21,87,17,16	NA mg/L	—
Placebo	Change From Baseline in hsCRP - Observed Data	Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-3.75 mg/L	Standard Deviation 29.301
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	NA mg/L	—
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk12,n=133,119,128,131,39,39,23,22,96,17,18	-9.72 mg/L	Standard Deviation 25.787
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,85,18,15	NA mg/L	—
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk4,n=131,134,129,133,39,38,23,21,97,17,19	-6.70 mg/L	Standard Deviation 20.732
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk48,n=97,91,na,na,28,29,20,19,79,13,14	NA mg/L	—
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk24,n=121,113,116,120,37,36,21,22,86,16,18	-8.66 mg/L	Standard Deviation 21.574
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk16,n=129,120,121,131,36,38,21,21,96,16,19	-8.37 mg/L	Standard Deviation 22.571
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk32,n=107,101,na,na,34,32,20,21,87,17,16	NA mg/L	—
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk2,n=133,129,133,135,39,36,23,21,100,17,18	-6.36 mg/L	Standard Deviation 19.416
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk52,n=95,92,na,na,29,28,20,18,83,16,16	NA mg/L	—
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,18	NA mg/L	—
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-5.64 mg/L	Standard Deviation 18.55
Abatacept	Change From Baseline in hsCRP - Observed Data	WK40,n=101,96,na,na,29,29,22,20,86,15,17	NA mg/L	—
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-9.43 mg/L	Standard Deviation 23.212
Abatacept	Change From Baseline in hsCRP - Observed Data	Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-8.48 mg/L	Standard Deviation 21.134
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk48,n=97,91,na,na,28,29,20,19,79,13,14	-10.49 mg/L	Standard Deviation 25.564
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-5.33 mg/L	Standard Deviation 20.645
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk2,n=133,129,133,135,39,36,23,21,100,17,18	0.43 mg/L	Standard Deviation 15.333
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk12,n=133,119,128,131,39,39,23,22,96,17,18	2.11 mg/L	Standard Deviation 18.312
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-0.33 mg/L	Standard Deviation 10.43
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	-6.66 mg/L	Standard Deviation 23.396
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,85,18,15	-4.21 mg/L	Standard Deviation 27.424
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk32,n=107,101,na,na,34,32,20,21,87,17,16	-4.34 mg/L	Standard Deviation 23.742
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk52,n=95,92,na,na,29,28,20,18,83,16,16	-4.63 mg/L	Standard Deviation 25.795
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk4,n=131,134,129,133,39,38,23,21,97,17,19	2.23 mg/L	Standard Deviation 23.317
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk24,n=121,113,116,120,37,36,21,22,86,16,18	-7.06 mg/L	Standard Deviation 20.298
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,18	-4.43 mg/L	Standard Deviation 21.777
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	WK40,n=101,96,na,na,29,29,22,20,86,15,17	-7.07 mg/L	Standard Deviation 26.156
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-4.72 mg/L	Standard Deviation 18.766
Placebo Non-responder - AIN457 75 mg	Change From Baseline in hsCRP - Observed Data	Wk16,n=129,120,121,131,36,38,21,21,96,16,19	3.92 mg/L	Standard Deviation 23.403
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk24,n=121,113,116,120,37,36,21,22,86,16,18	-11.46 mg/L	Standard Deviation 26.373
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-0.84 mg/L	Standard Deviation 24.777
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk2,n=133,129,133,135,39,36,23,21,100,17,18	-5.48 mg/L	Standard Deviation 17.301
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk4,n=131,134,129,133,39,38,23,21,97,17,19	-1.94 mg/L	Standard Deviation 21.927
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-3.28 mg/L	Standard Deviation 25.501
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk12,n=133,119,128,131,39,39,23,22,96,17,18	-2.89 mg/L	Standard Deviation 20.763
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk16,n=129,120,121,131,36,38,21,21,96,16,19	-2.13 mg/L	Standard Deviation 24.422
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-7.77 mg/L	Standard Deviation 27.581
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,18	-11.10 mg/L	Standard Deviation 27.186
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk32,n=107,101,na,na,34,32,20,21,87,17,16	-9.08 mg/L	Standard Deviation 25.867
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,85,18,15	-2.35 mg/L	Standard Deviation 37.226
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	WK40,n=101,96,na,na,29,29,22,20,86,15,17	2.39 mg/L	Standard Deviation 32.966
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	-8.53 mg/L	Standard Deviation 19.97
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk48,n=97,91,na,na,28,29,20,19,79,13,14	-4.76 mg/L	Standard Deviation 15.784
Placebo Non-responder - AIN457 150 mg	Change From Baseline in hsCRP - Observed Data	Wk52,n=95,92,na,na,29,28,20,18,83,16,16	-4.79 mg/L	Standard Deviation 22.882
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk32,n=107,101,na,na,34,32,20,21,87,17,16	-5.02 mg/L	Standard Deviation 10.3
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	-6.50 mg/L	Standard Deviation 19.968
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk12,n=133,119,128,131,39,39,23,22,96,17,18	-2.74 mg/L	Standard Deviation 12.899
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-0.40 mg/L	Standard Deviation 12.244
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	WK40,n=101,96,na,na,29,29,22,20,86,15,17	-4.46 mg/L	Standard Deviation 22.808
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk16,n=129,120,121,131,36,38,21,21,96,16,19	-5.67 mg/L	Standard Deviation 9.583
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk20,n=124,116,120,127,38,37,23,21,91,17,19	3.23 mg/L	Standard Deviation 48.634
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,18	-7.97 mg/L	Standard Deviation 18.018
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk48,n=97,91,na,na,28,29,20,19,79,13,14	-1.43 mg/L	Standard Deviation 33.122
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk8,n=134,128,130,132,39,39,23,22,96,17,19	0.13 mg/L	Standard Deviation 18.061
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk52,n=95,92,na,na,29,28,20,18,83,16,16	2.95 mg/L	Standard Deviation 9.88
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,85,18,15	-2.73 mg/L	Standard Deviation 21.272
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk2,n=133,129,133,135,39,36,23,21,100,17,18	-1.70 mg/L	Standard Deviation 11.17
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk4,n=131,134,129,133,39,38,23,21,97,17,19	-6.47 mg/L	Standard Deviation 12.458
Placebo Responder - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk24,n=121,113,116,120,37,36,21,22,86,16,18	-6.40 mg/L	Standard Deviation 11.562
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,18	0.09 mg/L	Standard Deviation 24.933
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk48,n=97,91,na,na,28,29,20,19,79,13,14	-6.97 mg/L	Standard Deviation 13.68
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-1.06 mg/L	Standard Deviation 15.737
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-1.50 mg/L	Standard Deviation 12.839
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk52,n=95,92,na,na,29,28,20,18,83,16,16	-4.88 mg/L	Standard Deviation 11.707
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	WK40,n=101,96,na,na,29,29,22,20,86,15,17	-4.73 mg/L	Standard Deviation 13.502
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	-7.27 mg/L	Standard Deviation 13.887
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk16,n=129,120,121,131,36,38,21,21,96,16,19	-4.29 mg/L	Standard Deviation 13.497
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk32,n=107,101,na,na,34,32,20,21,87,17,16	-5.51 mg/L	Standard Deviation 14.279
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk4,n=131,134,129,133,39,38,23,21,97,17,19	-1.95 mg/L	Standard Deviation 12.09
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-1.50 mg/L	Standard Deviation 7.541
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk2,n=133,129,133,135,39,36,23,21,100,17,18	-4.78 mg/L	Standard Deviation 10.515
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk12,n=133,119,128,131,39,39,23,22,96,17,18	2.10 mg/L	Standard Deviation 22.545
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,85,18,15	-6.78 mg/L	Standard Deviation 13.94
Placebo Responder - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk24,n=121,113,116,120,37,36,21,22,86,16,18	0.45 mg/L	Standard Deviation 18.244
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk24,n=121,113,116,120,37,36,21,22,86,16,18	-11.72 mg/L	Standard Deviation 22.198
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk52,n=95,92,na,na,29,28,20,18,83,16,16	-11.19 mg/L	Standard Deviation 27.768
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	-12.32 mg/L	Standard Deviation 25.47
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk2,n=133,129,133,135,39,36,23,21,100,17,18	-7.52 mg/L	Standard Deviation 20.301
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk16,n=129,120,121,131,36,38,21,21,96,16,19	-11.25 mg/L	Standard Deviation 23.692
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk32,n=107,101,na,na,34,32,20,21,87,17,16	-12.83 mg/L	Standard Deviation 23.33
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-6.40 mg/L	Standard Deviation 20.458
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk12,n=133,119,128,131,39,39,23,22,96,17,18	-12.17 mg/L	Standard Deviation 25.813
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,85,18,15	-12.19 mg/L	Standard Deviation 24.535
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk48,n=97,91,na,na,28,29,20,19,79,13,14	-13.90 mg/L	Standard Deviation 25.636
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,18	-12.08 mg/L	Standard Deviation 22.791
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-10.13 mg/L	Standard Deviation 22.724
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	WK40,n=101,96,na,na,29,29,22,20,86,15,17	-12.63 mg/L	Standard Deviation 23.788
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-11.59 mg/L	Standard Deviation 24.271
Abatacept Responders	Change From Baseline in hsCRP - Observed Data	Wk4,n=131,134,129,133,39,38,23,21,97,17,19	-7.53 mg/L	Standard Deviation 22.982
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-2.92 mg/L	Standard Deviation 12.405
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,18	-4.51 mg/L	Standard Deviation 14.144
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk16,n=129,120,121,131,36,38,21,21,96,16,19	-1.41 mg/L	Standard Deviation 8.81
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk32,n=107,101,na,na,34,32,20,21,87,17,16	-4.26 mg/L	Standard Deviation 15.329
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk12,n=133,119,128,131,39,39,23,22,96,17,18	-4.18 mg/L	Standard Deviation 16.024
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,85,18,15	-4.38 mg/L	Standard Deviation 14.479
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-.54 mg/L	Standard Deviation 14.849
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	WK40,n=101,96,na,na,29,29,22,20,86,15,17	-2.75 mg/L	Standard Deviation 17.297
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk4,n=131,134,129,133,39,38,23,21,97,17,19	-4.42 mg/L	Standard Deviation 14.991
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	-1.33 mg/L	Standard Deviation 4.846
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk2,n=133,129,133,135,39,36,23,21,100,17,18	-3.84 mg/L	Standard Deviation 13.737
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk52,n=95,92,na,na,29,28,20,18,83,16,16	-6.73 mg/L	Standard Deviation 14.972
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk48,n=97,91,na,na,28,29,20,19,79,13,14	-3.50 mg/L	Standard Deviation 21.343
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-3.94 mg/L	Standard Deviation 15.716
Abatacept Non-respnders - AIN457 75mg	Change From Baseline in hsCRP - Observed Data	Wk24,n=121,113,116,120,37,36,21,22,86,16,18	-4.94 mg/L	Standard Deviation 13.605
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk8,n=134,128,130,132,39,39,23,22,96,17,19	-4.59 mg/L	Standard Deviation 16.603
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk36,n=107,98,na,na,32,31,21,20,85,18,15	-0.47 mg/L	Standard Deviation 27.932
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk24,n=121,113,116,120,37,36,21,22,86,16,18	2.63 mg/L	Standard Deviation 20.875
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk48,n=97,91,na,na,28,29,20,19,79,13,14	-4.48 mg/L	Standard Deviation 16.918
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk1,n=134,130,131,131,39,36,21,22,97,17,17	-4.07 mg/L	Standard Deviation 10.811
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk2,n=133,129,133,135,39,36,23,21,100,17,18	-2.30 mg/L	Standard Deviation 19.035
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk12,n=133,119,128,131,39,39,23,22,96,17,18	-1.94 mg/L	Standard Deviation 31.483
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk32,n=107,101,na,na,34,32,20,21,87,17,16	-7.14 mg/L	Standard Deviation 17.446
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk52,n=95,92,na,na,29,28,20,18,83,16,16	-5.78 mg/L	Standard Deviation 18.534
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk16,n=129,120,121,131,36,38,21,21,96,16,19	0.32 mg/L	Standard Deviation 22.024
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk28,n=119,110,na,na,34,35,21,21,89,17,18	-1.70 mg/L	Standard Deviation 22.671
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk44,n=97,92,na,na,,28,28,20,19,85,15,16	-3.69 mg/L	Standard Deviation 24.389
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk4,n=131,134,129,133,39,38,23,21,97,17,19	-4.50 mg/L	Standard Deviation 11.029
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	Wk20,n=124,116,120,127,38,37,23,21,91,17,19	-3.99 mg/L	Standard Deviation 32.871
Abatacept Non-responders - AIN457 150mg	Change From Baseline in hsCRP - Observed Data	WK40,n=101,96,na,na,29,29,22,20,86,15,17	-7.95 mg/L	Standard Deviation 18.343

Secondary

Change From Baseline in Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)

Time frame: baseline, week 24

Arm	Measure	Value (LEAST_SQUARES_MEAN)	Dispersion
AIN457 10mg/kg - 75 mg	Change From Baseline in Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)	-0.30 score on a scale	Standard Error 0.049
AIN457 10mg/kg - 150 mg	Change From Baseline in Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)	-0.39 score on a scale	Standard Error 0.051
Placebo	Change From Baseline in Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)	-0.26 score on a scale	Standard Error 0.065
Abatacept	Change From Baseline in Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)	-0.61 score on a scale	Standard Error 0.053

Secondary

Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data

ACR20, ACR 50 and ACR 70 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20%, 50% and/or 70% improvement, respectively, in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire \[HAQ-DI\] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR20, ACR50 and ACR70 response results from baseline up to week 52 were based on observed data, i.e. without imputation.

Time frame: baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

Arm	Measure	Group	Value (NUMBER)
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,17,17	22.7 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,16,18	45.3 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,17,18	30.8 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	6.5 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19	9.1 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,16,19	39.3 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18	10.0 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	3.1 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19	15.6 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19	15.9 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,17,18	26.7 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	6.0 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,16,19	38.1 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	4.8 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	6.1 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	6.6 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	47.8 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	56.7 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	1.5 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	56.9 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	4.5 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	53.1 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	8.3 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16	23.5 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16	56.7 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16	27.8 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,17,19	38.6 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	9.6 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18	1.5 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17	25.0 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17	21.2 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14	57.4 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.8 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15	56.5 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17	6.8 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14	25.5 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	6.3 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19	13.9 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15	26.1 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18	5.3 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	12.4 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18	14.5 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,17,19	36.1 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	5.9 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19	9.8 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16	24.7 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	12.7 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	11.8 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	10.0 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	17.5 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,17,19	44.9 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17	32.0 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19	31.1 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18	22.7 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,17,19	28.0 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,17,18	40.0 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19	21.9 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19	23.7 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,16,19	45.8 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18	15.7 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19	16.5 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,16,18	48.2 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,16,19	51.8 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,17,17	18.6 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19	10.6 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14	42.7 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18	9.2 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15	45.5 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17	3.1 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15	62.5 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.8 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16	30.0 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14	68.5 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18	0.8 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16	61.1 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	61.1 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	3.0 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	53.8 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	4.7 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	61.9 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	65.0 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	3.5 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17	25.6 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	19.3 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	9.3 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	20.2 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	18.9 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	8.8 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,17,18	22.3 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	11.1 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	8.5 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18	14.5 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	3.1 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	3.4 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18	1.5 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,17,19	22.1 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,16,19	27.6 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19	11.2 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18	11.4 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19	12.6 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.0 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19	10.7 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	3.3 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,16,18	40.2 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,16,19	42.9 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,17,18	27.6 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,17,18	12.7 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19	3.1 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	1.5 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,17,17	7.7 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,17,19	22.9 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	6.7 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.8 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	NA Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18	3.0 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18	3.0 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17	1.5 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18	33.1 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,17,19	52.7 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.8 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,17,19	34.1 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18	0.7 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	10.0 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	14.9 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	11.1 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	1.6 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,17,18	25.4 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	6.1 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,16,19	55.8 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19	26.4 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18	24.8 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19	20.6 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,17,18	51.2 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,16,19	57.9 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	10.9 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19	7.8 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,16,18	57.9 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19	31.7 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14	NA Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,17,17	11.5 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,16,19	2.8 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,17,18	2.6 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,17,17	5.1 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,17,19	15.4 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,17,19	17.9 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,17,18	15.4 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,16,19	42.1 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,16,18	26.3 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14	14.3 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15	10.7 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	3.3 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	7.1 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	3.6 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	33.3 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	51.5 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	46.7 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	53.6 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16	50.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14	53.6 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15	39.3 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19	5.1 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18	2.6 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19	7.9 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18	0.0 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19	6.1 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17	6.1 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16	16.7 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17	14.3 Percentage of participants
Placebo Non-responder - AIN457 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16	7.1 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18	0.0 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	0.0 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18	0.0 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14	23.1 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16	55.6 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18	11.1 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16	16.7 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.0 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.0 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14	61.5 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15	26.9 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	8.3 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,17,19	12.8 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	11.1 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15	57.7 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,17,19	12.8 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19	8.6 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	0.0 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19	5.1 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	7.7 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	15.4 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,17,18	11.1 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	10.7 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	0.0 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	3.3 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,16,19	29.7 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,17,18	16.2 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18	8.1 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16	29.6 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	37.1 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19	2.7 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19	0.0 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	2.6 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,17,17	5.7 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17	13.3 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	36.7 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,16,18	33.3 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19	0.0 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	0.0 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17	28.6 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	56.7 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	2.9 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	0.0 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	53.6 Percentage of participants
Placebo Non-responder - AIN457 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,16,19	2.7 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	19.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,17,17	14.3 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,16,18	57.1 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18	4.3 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,17,18	47.8 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16	28.6 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19	33.3 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18	21.7 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	19.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16	85.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16	35.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14	38.9 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	14.3 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	81.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17	4.8 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18	38.1 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17	42.9 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	14.3 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17	38.1 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14	72.2 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	33.3 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	4.3 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	85.7 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	71.4 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,17,19	43.5 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18	13.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15	40.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,17,18	34.8 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	25.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19	8.7 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15	75.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	21.7 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19	34.8 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,17,19	39.1 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19	38.1 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19	34.8 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	13.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	13.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	85.7 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,16,19	76.2 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	30.0 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,16,19	60.9 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	23.8 Percentage of participants
Placebo Responder - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	23.8 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16	33.3 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19	33.3 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19	22.7 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	10.5 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,17,18	52.4 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19	14.3 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	0.0 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,17,18	13.6 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	0.0 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,17,19	31.8 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18	22.7 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	4.8 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	16.7 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,16,18	59.1 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	10.5 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	0.0 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,17,17	13.6 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	90.5 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	9.1 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	68.4 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	14.3 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	4.8 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	65.0 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18	4.5 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	73.7 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16	20.0 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17	26.3 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16	77.8 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	4.5 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.0 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14	57.9 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15	44.4 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15	88.9 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	11.1 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,17,19	42.9 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.0 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	14.3 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17	31.6 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14	26.3 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18	4.5 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,16,19	47.6 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19	9.5 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19	9.1 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,16,19	63.6 Percentage of participants
Placebo Responder - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18	23.8 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,16,19	76.6 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18	30.9 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14	48.1 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19	41.9 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16	77.4 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	13.8 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	15.4 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	71.8 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18	1.0 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19	40.7 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18	3.0 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	77.6 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	2.2 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	74.7 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	17.4 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	27.3 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	23.5 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	19.5 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	21.2 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	74.4 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19	36.2 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19	10.8 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	7.4 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16	50.0 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16	47.1 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,16,18	69.0 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,16,19	73.6 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	22.8 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	21.8 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,17,17	14.6 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,17,18	29.3 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,17,18	62.8 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19	25.3 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15	74.7 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	14.9 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18	44.8 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15	51.9 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14	71.4 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,17,19	41.9 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	26.2 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17	47.1 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17	45.9 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17	1.0 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,17,19	61.1 Percentage of participants
Abatacept Responders	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17	1.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19	11.8 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	13.3 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	6.7 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,17,17	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	13.3 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,16,18	31.3 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	5.9 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	41.2 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	27.8 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	40.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16	33.3 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14	25.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15	20.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17	20.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15	40.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,16,19	6.3 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	23.5 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	11.1 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,16,19	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18	5.9 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,17,18	17.6 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,17,19	29.4 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,17,18	11.8 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19	23.5 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,17,19	17.6 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17	5.9 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16	13.3 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	5.9 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	0.0 Percentage of participants
Abatacept Non-respnders - AIN457 75mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16	16.7 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19	5.3 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,16,19	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,17,19	10.5 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,17,17	5.9 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,16,19	26.3 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18	5.6 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17	5.9 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17	5.9 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15	33.3 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15	13.3 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14	50.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16	18.8 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16	31.3 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17	58.8 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16	56.3 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17	47.1 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16	6.3 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18	5.6 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19	42.1 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,16,18	27.8 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18	5.6 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,17,18	16.7 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19	15.8 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,17,19	31.6 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,17,18	22.2 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18	11.1 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16	0.0 Percentage of participants
Abatacept Non-responders - AIN457 150mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data	ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19	0.0 Percentage of participants

Secondary

Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation

Time frame: baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24

Population: Participants from the full analysis set were considered for the analysis. Participants with missing data were considered non-responders at the respective time point. Placebo and Abatacept participants were considered non-responders from the time of treatment switch.

Arm	Measure	Group	Value (NUMBER)
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 4	9.4 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 12	2.2 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 24	5.1 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 24	11.6 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 1	0.7 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 2	1.4 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 4	4.3 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 8	1.4 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 1	21.0 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 2	24.6 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 4	34.1 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 8	35.5 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 12	28.3 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 16	34.1 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 20	26.8 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 24	28.3 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 1	6.5 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 2	5.1 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 8	7.2 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 12	8.7 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 16	13.8 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 20	12.3 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 16	5.1 Percentage of participants
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 20	4.3 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 8	4.4 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 16	39.4 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 2	21.2 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 4	2.9 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 4	10.2 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 20	38.0 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 12	13.1 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 2	8.8 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 12	2.9 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 24	30.7 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 16	8.0 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 1	2.9 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 1	17.5 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 4	27.0 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 1	0.7 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 20	18.2 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 24	10.2 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 8	41.6 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 24	16.8 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 20	7.3 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 2	0.7 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 12	33.6 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 16	20.4 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 8	15.3 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 4	2.9 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 4	1.4 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 16	2.9 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 1	7.2 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 2	12.3 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 16	9.4 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 4	21.7 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 8	21.0 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 12	24.6 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 16	23.2 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 20	18.1 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 24	18.1 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 12	2.9 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 1	0.7 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 2	2.9 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 20	5.8 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 8	2.9 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 8	10.1 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 24	5.1 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 20	8.0 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 24	9.4 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 1	0.0 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 12	10.1 Percentage of participants
Placebo	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 2	1.4 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 12	47.1 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 16	9.4 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 20	10.1 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 4	1.4 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 8	49.3 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 8	18.8 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 16	23.9 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 12	22.5 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 24	12.3 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 4	31.2 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 1	0.7 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 20	26.8 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 2	23.9 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 24	42.8 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 1	10.9 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 1	1.4 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 12	9.4 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 20	47.8 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 2	0.7 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 2	2.9 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR70, week 8	5.8 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR20, week 16	51.4 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 4	7.2 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation	ACR50, week 24	27.5 Percentage of participants

Secondary

Percentage of Participants Achieving ACR50

ACR50 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 50% improvement in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire \[HAQ-DI\] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR50 response results at week 24 used non-responder imputation.

Time frame: week 24

Population: Full analysis set: the full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.

Arm	Measure	Value (NUMBER)
AIN457 10mg/kg - 75 mg	Percentage of Participants Achieving ACR50	11.6 Percentage of participants
AIN457 10mg/kg - 150 mg	Percentage of Participants Achieving ACR50	16.8 Percentage of participants
Placebo	Percentage of Participants Achieving ACR50	9.4 Percentage of participants
Abatacept	Percentage of Participants Achieving ACR50	27.5 Percentage of participants

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20).

Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP)

Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data

Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM

Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data

Change From Baseline in HAQ-DI - Observed Data

Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)

Change From Baseline in hsCRP - Observed Data

Change From Baseline in Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)

Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data

Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation

Percentage of Participants Achieving ACR50